Reported
Lowest–highest estimate
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Pacific Biosciences of California Inc
F:P09
Pacific Biosciences of California Inc
F:P09
Price:
22.77
EUR
2.34%
Market Closed
Market Cap:
€1.7B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
P
|
Pacific Biosciences of California Inc
F:P09
|
US |
|
S
|
SSP Group PLC
F:83S2
|
UK |
|
5N Plus Inc
F:EMB
|
CA |
Wall St Price Targets
P09 Price Forecast
Based on 10 analysts
Based on 10 analysts
-89% Downside
from
€22.77
today
Pacific Biosciences of California Inc (P09)’s 12-month stock price forecast through August 2022 has a consensus target of €2.42, implying 89% downside. The forecast is based on price targets from 10 Wall Street analysts.
P09 Analyst Rating
No ratings yet
No ratings yet
Pacific Biosciences of California Inc Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is P09's stock price target?
Price Target
2.42
EUR
2.42
EUR
According to Wall Street analysts, the average 1-year price target for P09 is 2.42 EUR with a low forecast of 1.5 EUR and a high forecast of 3.73 EUR.
What is the Revenue forecast for Pacific Biosciences of California Inc?
Projected CAGR
17%
17%
Over the last 13 years, the compound annual growth rate for Revenue has been 15%. The projected CAGR for the next 8 years is 17%.
What is the Gross Profit forecast for Pacific Biosciences of California Inc?
Projected CAGR
26%
26%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 36%. The projected CAGR for the next 3 years is 26%.